Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.

Autor: Aden D; Department of Pathology, Hamdard Institute of Medical Science and Research, New Delhi, India., Sureka N; Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India., Zaheer S; Department of Radiotherapy, Jawaharlal Nehru Medical College, AMU, Aligarh, India., Chaurasia JK; Department of Pathology and Laboratory Medicine, AIIMS, Bhopal, India., Zaheer S; Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Jazyk: angličtina
Zdroj: Immunology [Immunology] 2024 Oct 27. Date of Electronic Publication: 2024 Oct 27.
DOI: 10.1111/imm.13871
Abstrakt: Cancer is a complex and heterogeneous disease characterised by uncontrolled cell growth and proliferation. One hallmark of cancer cells is their ability to undergo metabolic reprogramming, which allows them to sustain their rapid growth and survival. This metabolic reprogramming creates an immunosuppressive microenvironment that facilitates tumour progression and evasion of the immune system. In this article, we review the mechanisms underlying metabolic reprogramming in cancer cells and discuss how these metabolic alterations contribute to the establishment of an immunosuppressive microenvironment. We also explore potential therapeutic strategies targeting metabolic vulnerabilities in cancer cells to enhance immune-mediated anti-tumour responses. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02044861, NCT03163667, NCT04265534, NCT02071927, NCT02903914, NCT03314935, NCT03361228, NCT03048500, NCT03311308, NCT03800602, NCT04414540, NCT02771626, NCT03994744, NCT03229278, NCT04899921.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: